Respiratory Medicine

Papers
(The H4-Index of Respiratory Medicine is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19)275
Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae220
Diagnostic performance between CT and initial real-time RT-PCR for clinically suspected 2019 coronavirus disease (COVID-19) patients outside Wuhan, China190
Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians179
Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?138
Goals of COPD treatment: Focus on symptoms and exacerbations131
Pulmonary function and health-related quality of life after COVID-19 pneumonia117
A study on infectivity of asymptomatic SARS-CoV-2 carriers109
Underlying respiratory diseases, specifically COPD, and smoking are associated with severe COVID-19 outcomes: A systematic review and meta-analysis94
Levels of resilience, anxiety and depression in nurses working in respiratory clinical areas during the COVID pandemic89
Smoking and COVID-19: What we know so far79
Integrative respiratory follow-up of severe COVID-19 reveals common functional and lung imaging sequelae78
Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-1974
D-dimer in patients infected with COVID-19 and suspected pulmonary embolism69
The role of oral microbiome in respiratory health and diseases59
Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudin59
Significant reduction in hospital admissions for acute exacerbation of chronic obstructive pulmonary disease in Hong Kong during coronavirus disease 2019 pandemic56
Clinical outcomes and quality of life of COVID-19 survivors: A follow-up of 3 months post hospital discharge54
Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry52
COVID-19: Why does disease severity vary among individuals?51
Predictors of mortality in fibrosing pulmonary sarcoidosis48
Sex differences between women and men with COPD: A new analysis of the 3CIA study47
Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomis46
Correlation analysis of the severity and clinical prognosis of 32 cases of patients with COVID-1946
Pneumothorax in critically ill patients with COVID-19 infection: Incidence, clinical characteristics and outcomes in a case control multicenter study44
Respiratory rehabilitation for Covid-19 related persistent dyspnoea: A one-year experience44
Idiopathic pulmonary hemosiderosis: A state of the art review44
Colchicine and SARS-CoV-2: Management of the hyperinflammatory state42
Six-minute walk distance in healthy young adults42
Candida spp. co-infection in COVID-19 patients with severe pneumonia: Prevalence study and associated risk factors41
Health-related quality of life profiles, trajectories, persistent symptoms and pulmonary function one year after ICU discharge in invasively ventilated COVID-19 patients, a prospective follow-up study41
“Current place of impulse oscillometry in the assessment of pulmonary diseases.”40
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity40
Evaluation and management of pulmonary arterial hypertension38
Residual ground glass opacities three months after Covid-19 pneumonia correlate to alteration of respiratory function: The post Covid M3 study37
Managing malnutrition in COPD: A review37
Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis37
0.034442901611328